文献速递胸部肿瘤

EGFR突变晚期NSCLC一线奥希替尼单药长期获益的预测因素与探索性临床评分

Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.
PubMed 文献 · J Thorac Oncol · 2026-09-21

该回顾性队列纳入25家日本机构803例接受一线奥希替尼单药治疗的EGFR突变晚期或复发NSCLC患者,204例(25.4%)获得长期获益(LTB,定义为PFS≥24个月且OS≥48个月)。多因素分析确定6个独立相关因素并构建0-6分探索性评分,评分越高LTB率及PFS、OS越长。

要点

  • LTB定义为PFS≥24个月且OS≥48个月,803例中204例(25.4%)达到LTB。
  • 6个有利因素:年龄<75岁、ECOG PS 0-1、白蛋白≥3.5 g/dL、术后复发、EGFR exon 19缺失、无肝转移。
  • 0-2分、3-4分、5-6分组的LTB率分别为2.5%、19.0%、50.7%(趋势p<0.001)。

核心结论

  • 该探索性评分可能有助于对奥希替尼单药持久获益可能性进行预后分层,但不能确定单药是否应优先于强化方案。

研究设计与样本

  • 回顾性队列研究,纳入2018年9月至2022年3月在日本25家机构接受一线奥希替尼单药治疗的晚期或复发EGFR突变NSCLC患者803例。
  • LTB定义为PFS≥24个月且OS≥48个月,参照FLAURA2试验;采用多因素logistic回归评估LTB相关因素。

主要发现

  • 803例中204例(25.4%)发生LTB。
  • 6个独立相关有利因素为:年龄<75岁、ECOG PS 0-1、血清白蛋白≥3.5 g/dL、术后复发、EGFR exon 19缺失、无肝转移。
  • 0-2分、3-4分、5-6分组LTB率分别为2.5%、19.0%、50.7%(趋势p<0.001)。
  • 0-2分、3-4分、5-6分组中位PFS分别为7.2、16.8、30.5个月,中位OS分别为12.7、35.9、68.3个月。

关键数值与推荐

  • 6个有利因素各计1分,构建0-6分探索性评分。
  • LTB率:0-2分组2.5%,3-4分组19.0%,5-6分组50.7%(趋势p<0.001)。
  • 中位PFS:0-2分组7.2个月,3-4分组16.8个月,5-6分组30.5个月。
  • 中位OS:0-2分组12.7个月,3-4分组35.9个月,5-6分组68.3个月。

临床怎么用

  • 该探索性评分可用于与患者沟通奥希替尼单药获得长期获益的可能性,辅助预后分层。
  • 评分不能作为选择单药或强化一线治疗的依据,原文未确立单药优先于强化方案。

局限性

  • 回顾性队列设计。
  • 评分为探索性,未验证。
  • 不能确定单药是否应优先于强化方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: First-line osimertinib monotherapy remains a standard treatment for advanced EGFR-mutated NSCLC, although intensified regimens improve outcomes at the cost of increased toxicity and treatment burden. We characterized pretreatment clinical features associated with long-term benefit (LTB) and developed an exploratory clinical score. METHODS: This retrospective cohort comprised patients who received first-line osimertinib monotherapy for advanced or recurrent EGFR-mutated NSCLC at 25 Japanese institutions between September 2018 and March 2022. In this study, LTB was defined as both progression-free survival of 24 months or longer and overall survival of 48 months or longer, based on the FLAURA2 trial. Factors associated with LTB were evaluated using multivariable logistic regression. Six independently associated favorable factors were each assigned a score of 1 if present, yielding an exploratory 0- to 6-point score. RESULTS: Among the 803 included patients, 204 (25.4%) experienced an LTB. The six factors independently associated factors were age of less than 75 years, an Eastern Cooperative Oncology Group performance status of 0 to 1, a serum albumin level of 3.5 g/dL or higher, postoperative recurrence, EGFR exon 19 deletion, and the absence of liver metastasis. Rates of LTB were 2.5%, 19.0%, and 50.7% in the 0- to 2-, 3- to 4-, and 5- to 6-point groups, respectively (p for trend < 0.001). The median progression-free survival was 7.2, 16.8, and 30.5 months, respectively, and the median overall survival was 12.7, 35.9, and 68.3 months, respectively. CONCLUSIONS: This exploratory score may support prognostic stratification regarding the likelihood of durable outcomes with osimertinib monotherapy, but it does not establish whether monotherapy should be preferred over an intensified regimen.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ishida M, Yamada T, Yamaguchi O, et al. Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy. J Thorac Oncol. 2026. PMID: 42767607. doi:10.1016/j.jtho.2026.106103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。